Corrêa Michelle F, Barbosa Álefe J R, Teixeira Larissa B, Duarte Diego A, Simões Sarah C, Parreiras-E-Silva Lucas T, Balbino Aleksandro M, Landgraf Richardt G, Bouvier Michel, Costa-Neto Claudio M, Fernandes João P S
Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo, Diadema, Brazil.
Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Front Pharmacol. 2017 Nov 14;8:825. doi: 10.3389/fphar.2017.00825. eCollection 2017.
The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, HR and HR subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting HR/HR ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine (LINS01 series) molecules were synthesized and evaluated as HR and HR ligands. Our data show that the -allyl-substituted compound LINS01004 bears the highest affinity for HR (p 6.40), while the chlorinated compound LINS01007 has moderate affinity for HR (p 6.06). In addition, BRET assays to assess the functional activity of G1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory.
组胺受体(HRs)是具有广泛治疗意义的传统G蛋白偶联受体。最近,在针对炎症、哮喘、疼痛、癌症、帕金森病和阿尔茨海默病的药物研发项目中,HR及其亚型已成为靶点,其中包括寻找双效HR/HR配体。在本研究中,合成了9种1-[(2,3-二氢-1-苯并呋喃-2-基)甲基]哌嗪(LINS01系列)分子,并对其作为HR和HR配体进行了评估。我们的数据表明,烯丙基取代的化合物LINS01004对HR具有最高亲和力(p 6.40),而氯化化合物LINS01007对HR具有中等亲和力(p 6.06)。此外,用于评估G1偶联功能活性的BRET分析表明,所有化合物均无内在活性,可作为这些受体的拮抗剂。类药性质评估表明,这些分子是有望进一步优化的先导化合物。在哮喘小鼠模型中对化合物LINS01005和LINS01007进行的评估显示,LINS01007(3 g/kg)的抗炎活性优于先前测试的化合物LINS01005。这是关于这些化合物在HRs中功能数据的首次报道,我们的结果还显示了它们作为抗炎药的应用潜力。